Remus Pharmaceuticals Limited (NSE:REMUS)
India · Delayed Price · Currency is INR 819.35
-0.65 (-0.08%)
At close: Sep 16, 2025
Remus Pharmaceuticals Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2020 |
Operating Revenue | 6,204 | 2,125 | 450.27 | 247.17 | 184.18 | Upgrade |
Other Revenue | - | 3.59 | 1.05 | - | 3.9 | Upgrade |
| 6,204 | 2,129 | 451.32 | 247.17 | 188.08 | Upgrade | |
Revenue Growth (YoY) | 191.44% | 371.63% | 82.59% | 31.42% | 51.44% | Upgrade |
Cost of Revenue | 5,329 | 1,644 | 214.69 | 122.81 | 115.04 | Upgrade |
Gross Profit | 874.9 | 484.2 | 236.63 | 124.36 | 73.04 | Upgrade |
Selling, General & Admin | 131.1 | 74.23 | 54.7 | 34.24 | 29.95 | Upgrade |
Other Operating Expenses | 286.9 | 121.35 | 70.45 | 46.32 | 29.71 | Upgrade |
Operating Expenses | 436.7 | 204.54 | 129.92 | 82.1 | 61.41 | Upgrade |
Operating Income | 438.2 | 279.65 | 106.71 | 42.26 | 11.63 | Upgrade |
Interest Expense | -14.6 | -4.49 | -2.04 | -0.78 | -0.29 | Upgrade |
Interest & Investment Income | - | 22.55 | 3.48 | 2.45 | 0.69 | Upgrade |
Currency Exchange Gain (Loss) | - | 5.73 | 6.24 | 2.22 | 0.53 | Upgrade |
Other Non Operating Income (Expenses) | 49.8 | -0.26 | -0.26 | -0.09 | -0.06 | Upgrade |
EBT Excluding Unusual Items | 473.4 | 303.19 | 114.14 | 46.06 | 12.5 | Upgrade |
Gain (Loss) on Sale of Investments | - | - | - | 0.08 | 1.08 | Upgrade |
Gain (Loss) on Sale of Assets | - | 15.1 | - | - | - | Upgrade |
Pretax Income | 473.4 | 318.29 | 114.14 | 46.13 | 13.58 | Upgrade |
Income Tax Expense | 89.2 | 58.52 | 29.11 | 11.79 | 3.32 | Upgrade |
Earnings From Continuing Operations | 384.2 | 259.77 | 85.03 | 34.34 | 10.26 | Upgrade |
Minority Interest in Earnings | -93.5 | -44.4 | - | - | - | Upgrade |
Net Income | 290.7 | 215.37 | 85.03 | 34.34 | 10.26 | Upgrade |
Net Income to Common | 290.7 | 215.37 | 85.03 | 34.34 | 10.26 | Upgrade |
Net Income Growth | 34.98% | 153.29% | 147.60% | 234.77% | 26.39% | Upgrade |
Shares Outstanding (Basic) | 9 | 11 | 8 | 8 | 8 | Upgrade |
Shares Outstanding (Diluted) | 9 | 11 | 8 | 8 | 8 | Upgrade |
Shares Change (YoY) | -21.35% | 38.79% | 2.10% | - | - | Upgrade |
EPS (Basic) | 32.61 | 19.00 | 10.41 | 4.29 | 1.28 | Upgrade |
EPS (Diluted) | 32.61 | 19.00 | 10.41 | 4.29 | 1.28 | Upgrade |
EPS Growth | 71.62% | 82.51% | 142.51% | 234.77% | 26.39% | Upgrade |
Free Cash Flow | -41.4 | 29.67 | 25.81 | 49.67 | 27.72 | Upgrade |
Free Cash Flow Per Share | -4.64 | 2.62 | 3.16 | 6.21 | 3.46 | Upgrade |
Dividend Per Share | 0.750 | 0.750 | 0.250 | - | - | Upgrade |
Dividend Growth | - | 200.00% | - | - | - | Upgrade |
Gross Margin | 14.10% | 22.75% | 52.43% | 50.31% | 38.83% | Upgrade |
Operating Margin | 7.06% | 13.14% | 23.64% | 17.10% | 6.18% | Upgrade |
Profit Margin | 4.69% | 10.12% | 18.84% | 13.89% | 5.45% | Upgrade |
Free Cash Flow Margin | -0.67% | 1.39% | 5.72% | 20.09% | 14.74% | Upgrade |
EBITDA | 456.9 | 288.39 | 111.36 | 43.81 | 13.38 | Upgrade |
EBITDA Margin | 7.36% | 13.55% | 24.67% | 17.72% | 7.11% | Upgrade |
D&A For EBITDA | 18.7 | 8.73 | 4.64 | 1.55 | 1.75 | Upgrade |
EBIT | 438.2 | 279.65 | 106.71 | 42.26 | 11.63 | Upgrade |
EBIT Margin | 7.06% | 13.14% | 23.64% | 17.10% | 6.18% | Upgrade |
Effective Tax Rate | 18.84% | 18.39% | 25.50% | 25.56% | 24.47% | Upgrade |
Revenue as Reported | 6,253 | 2,179 | 466.05 | 254.37 | 192.25 | Upgrade |
Updated Mar 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.